This inventor holds 6 USPTO granted patents and 1 EPO patent. Top assignee: Eisai Company, Limited. Active years: 1992-2004.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Kagamigahara, JP (1992)
- Gifu, JP (2000)
- Gunma, JP (2001 - 2004)
Company Filing History:
Years Active: 1992-2004
Title: Hidenobu Ando: Innovator in Antidementia Medicaments
Introduction
Hidenobu Ando is a notable inventor based in Gunma, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antidementia medicaments. With a total of 6 patents to his name, Ando's work is recognized for its innovative approaches to medication delivery.
Latest Patents
Ando's latest patents include a percutaneously applicable preparation and a suppository containing an antidementia medicament. The invention provides a percutaneously applicable preparation that incorporates a higher alcohol, a lactate of a higher alcohol, an ester of a higher fatty acid and a lower alcohol, or an ester of a fatty acid having 6-18 carbon atoms and propylene glycol. Additionally, it offers a rectum applicable preparation containing an antidementia medicament, which includes a triglyceride of a fatty acid and/or a water-soluble macromolecule.
Career Highlights
Hidenobu Ando is currently associated with Eisai Company, Limited, a prominent player in the pharmaceutical industry. His work focuses on creating effective treatments for dementia, showcasing his commitment to improving patient care through innovative solutions.
Collaborations
Ando has collaborated with notable colleagues such as Naokazu Murahashi and Akira Kato. These partnerships have contributed to the advancement of his research and the successful development of his inventions.
Conclusion
Hidenobu Ando's contributions to the field of antidementia medicaments highlight his innovative spirit and dedication to improving healthcare. His patents reflect a commitment to finding effective solutions for complex medical challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
